Trial Profile
A Randomized, Open-label Study of the Effect of NeoRecormon on Reduction of Cardiovascular Risk in Patients With Chronic Renal Anemia Who Are Not on Renal Replacement Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Jun 2016
Price :
$35
*
At a glance
- Drugs Epoetin beta (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Roche
- 02 Nov 2015 New trial record